.png){kind=icon}
返回
How does flecainide impact RyR2 channel function?
.png){kind=icon}
OA
AI
DOI：10.1085/jgp.202213089.png)
.png){kind=icon}
.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Flecainide, a cardiac class 1C blocker of the surface membrane sodium channel (Na(V)1.5), has also been reported to reduce cardiac ryanodine receptor (RyR2)-mediated sarcoplasmic reticulum (SR) Ca2+ release. It has been introduced as a clinical antiarrhythmic agent for catecholaminergic polymorphic ventricular tachycardia (CPVT), a condition most commonly associated with gain-of-function RyR2 mutations. Current debate concerns both cellular mechanisms of its antiarrhythmic action and molecular mechanisms of its RyR2 actions. At the cellular level, it targets Na(V)1.5, RyR2, Na+/Ca2+ exchange (NCX), and additional proteins involved in excitation-contraction (EC) coupling and potentially contribute to the CPVT phenotype. This Viewpoint primarily addresses the various direct molecular actions of flecainide on isolated RyR2 channels in artificial lipid bilayers. Such studies demonstrate different, multifarious, flecainide binding sites on RyR2, with voltage-dependent binding in the channel pore or voltage-independent binding at distant peripheral sites. In contrast to its single Na(V)1.5 pore binding site, flecainide may bind to at least four separate inhibitory sites on RyR2 and one activation site. None of these binding sites have been specifically located in the linear RyR2 sequence or high-resolution structure. Furthermore, it is not clear which of the inhibitory sites contribute to flecainide's reduction of spontaneous Ca2+ release in cellular studies. A confounding observation is that flecainide binding to voltage-dependent inhibition sites reduces cation fluxes in a direction opposite to physiological Ca2+ flow from SR lumen to cytosol. This may suggest that, rather than directly blocking Ca2+ efflux, flecainide can reduce Ca2+ efflux by blocking counter currents through the pore which otherwise limit SR membrane potential change during systolic Ca2+ efflux. In summary, the antiarrhythmic effects of flecainide in CPVT seem to involve multiple components of EC coupling and multiple actions on RyR2. Their clarification may identify novel specific drug targets and facilitate flecainide's clinical utilization in CPVT. The promiscuity of flecainide underscores its antiarrhythmic efficacy in CPVT: this paper presents a discussion of its mechanisms of action on the cardiac ryanodine receptor (RyR2) and other cardiac excitation-contraction coupling proteins.
Keyword:
POLYMORPHIC VENTRICULAR-TACHYCARDIA
CARDIAC RYANODINE RECEPTOR
CALCIUM-RELEASE CHANNEL
PAROXYSMAL ATRIAL-FIBRILLATION
CA2+ RELEASE
SARCOPLASMIC-RETICULUM
MOLECULAR DETERMINANTS
SODIUM-CHANNELS
NA+ CHANNELS
MOUSE MODEL
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
2.9
论文数:
3.3K
被引数:
7.2K
机构
引用论文
Increased Ca2+ Sensitivity of the Ryanodine Receptor Mutant RyR2R4496C Underlies Catecholaminergic Polymorphic Ventricular Tachycardia.png)
CIRCULATION RESEARCHOAAI
CIRCULATION RESEARCHIF16.2
OAAI分享收藏
Molecular basis of Ca2+ activation of the mouse cardiac Ca2+ release channel (ryanodine receptor)OAAI
OAAI分享收藏Cardiac Alternans Occurs through the Synergy of Voltage- and Calcium-Dependent MechanismsMEMBRANESOAAI
MEMBRANESIF3.6
OAAI分享收藏Loss-of-function mutations in cardiac ryanodine receptor channel cause various types of arrhythmias including long QT syndromeEUROPACE
EUROPACEIF7.4
PREAI
分享收藏Unique isoform-specific properties of calsequestrin in the heart and skeletal muscle钙蛋白在心脏和骨骼肌中的独特同工型特异性CELL CALCIUMOAAI
CELL CALCIUMIF4
OAAI分享收藏Calsequestrin is an inhibitor of skeletal muscle ryanodine receptor calcium release channelsBIOPHYSICAL JOURNALOAAI
BIOPHYSICAL JOURNALIF3.1
OAAI分享收藏
查看更多内容